Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-13
2007-02-13
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253130, C544S364000
Reexamination Certificate
active
11353307
ABSTRACT:
The present invention relates to compounds of the formulawherein R1and R1′are each independently hydrogen or methyl and X is —C(O)N(CH3)— or —N(CH3)C(O)—, and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic and psychosomatic disorders.
REFERENCES:
patent: 5972938 (1999-10-01), Rupniak et al.
patent: 1 035 115 (2000-09-01), None
patent: WO 95/16679 (1995-06-01), None
patent: WO 95/18124 (1995-07-01), None
patent: WO 95/23798 (1995-09-01), None
patent: WO 05/002577 (2005-01-01), None
Barker, R., Reviews in the Neuroscience, vol. 7, pp. 187-214, (1996).
Longmore et al., Can. J. Physiol. Pharmacol., vol. 75, pp. 612-621 (1997).
Kramer et al., Science, vol. 281, pp. 1640-1645, 1998.
Maggi et al., J. Auton. Pharmacol. vol. 13, pp. 23-93 (1993).
Navari et al., The New England Journal of Medicine, vol. 340, No. 3, pp. 190-195 (1999).
Hoffmann Torsten
Schnider Patrick
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Bi-pyridinyl derivatives as NK-1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bi-pyridinyl derivatives as NK-1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-pyridinyl derivatives as NK-1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880797